Institut für Zellbiologie und Immunologie, Universität Stuttgart, Allmandring 31, 70569 Stuttgart, Germany.
Protein Eng Des Sel. 2012 Oct;25(10):603-12. doi: 10.1093/protein/gzs059. Epub 2012 Sep 17.
Dimeric assembly of antibody fragments and other therapeutic molecules can result in increased binding and improved bioactivity. Here, we investigated the use of the IgM heavy chain domain 2 (MHD2) as covalently linked homodimerization module. Fusion of single-chain fragment variable (scFv) molecules directed against epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 to the N- and/or C-terminus of the MHD2, respectively, resulted in molecules with single or dual specificity for tumor cells. Bispecific tetravalent molecules were further generated by fusing a bispecific single-chain diabody directed against EGFR and epithelial cell adhesion molecule to the N-terminus of the MHD2. By combining an anti-EGFR scFv with a single-chain derivative of tumor necrosis factor, a tetravalent bifunctional fusion protein was produced. This fusion protein exhibited improved TNF activity, also mimicking the membrane-bound form of TNF, as shown by the activation of TNFR2-mediated cell killing. Furthermore, the scFv moiety allowed for an antigen-dependent delivery of TNF to EGFR-positive cells and an improved stimulatory TNF action on these cells. Thus, we established the MHD2 as a versatile module for the generation of bispecific and bifunctional fusion proteins.
抗体片段和其他治疗分子的二聚体组装可以导致结合增强和生物活性提高。在这里,我们研究了使用 IgM 重链结构域 2(MHD2)作为共价连接的同二聚化模块。将针对表皮生长因子受体(EGFR)和人表皮生长因子受体 2 的单链片段可变(scFv)分子分别融合到 MHD2 的 N-和/或 C-末端,产生了对肿瘤细胞具有单特异性或双特异性的分子。通过将针对 EGFR 和上皮细胞黏附分子的双特异性单链二抗体融合到 MHD2 的 N-末端,进一步生成了四价双特异性四聚体分子。通过将抗 EGFR scFv 与肿瘤坏死因子的单链衍生物结合,产生了四价双功能融合蛋白。该融合蛋白显示出改善的 TNF 活性,也模拟了 TNF 的膜结合形式,如 TNFR2 介导的细胞杀伤所显示的。此外,scFv 部分允许 TNF 依赖抗原递送到 EGFR 阳性细胞,并改善对这些细胞的 TNF 刺激作用。因此,我们将 MHD2 确立为用于产生双特异性和双功能融合蛋白的多功能模块。